Lea R Eisenbach

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4701430/publications.pdf

Version: 2024-02-01

85 papers	3,589 citations	172457 29 h-index	133252 59 g-index
87 all docs	87 docs citations	87 times ranked	4488 citing authors

#	Article	IF	Citations
1	On the development of a neoantigen vaccine for the prevention of Lynch Syndrome. International Journal of Cancer, 2022, , .	5.1	2
2	Avidity optimization of a MAGEâ€A1â€specific TCR with somatic hypermutation. European Journal of Immunology, 2021, 51, 1505-1518.	2.9	5
3	A universal antiâ€cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. International Journal of Cancer, 2019, 144, 909-921.	5.1	5
4	Optimizing Tâ€cell receptor avidity with somatic hypermutation. International Journal of Cancer, 2019, 145, 2816-2826.	5.1	8
5	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell, 2019, 179, 219-235.e21.	28.9	270
6	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. OncoImmunology, 2018, 7, e1445457.	4.6	13
7	Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 835-847.	3.3	17
8	The antiâ€inflammatory IFITM genes ameliorate colitis and partially protect from tumorigenesis by changing immunity and microbiota. Immunology and Cell Biology, 2018, 96, 284-297.	2.3	38
9	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. OncoImmunology, 2016, 5, e1160183.	4.6	4
10	mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity. Molecular Therapy, 2015, 23, 1391-1400.	8.2	16
11	Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. Cancer Immunology, Immunotherapy, 2014, 63, 369-380.	4.2	25
12	Development of novel genetic cancer vaccines based on membraneâ€attached Î²₂ microglobulin. Annals of the New York Academy of Sciences, 2013, 1283, 87-90.	3.8	2
13	The human ISG12a gene is a novel caspase dependent and p53 independent pro-apoptotic gene, that is overexpressed in breast cancer. Cell Biology International Reports, 2013, 20, 37-46.	0.6	10
14	Production of LacZ Inducible T Cell Hybridoma Specific for Human and Mouse gp10025â€“33 Peptides. PLoS ONE, 2013, 8, e55583.	2.5	8
15	Mouse Dendritic Cells Pulsed with Capsular Polysaccharide Induce Resistance to Lethal Pneumococcal Challenge: Roles of T Cells and B Cells. PLoS ONE, 2012, 7, e39193.	2.5	6
16	Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. International Immunology, 2011, 23, 453-461.	4.0	11
17	Split Immunity: Immune Inhibition of Rat Gliomas by Subcutaneous Exposure to Unmodified Live Tumor Cells. Journal of Immunology, 2011, 187, 5452-5462.	0.8	19
18	T cell vaccination induces the elimination of EAE effector T cells: Analysis using GFP-transduced, encephalitogenic T cells. Journal of Autoimmunity, 2010, 35, 135-144.	6.5	11

#	Article	IF	Citations
19	A Systems Immunology Approach to the Host-Tumor Interaction: Large-Scale Patterns of Natural Autoantibodies Distinguish Healthy and Tumor-Bearing Mice. PLoS ONE, 2009, 4, e6053.	2.5	36
20	The human 1â€8D gene (IFITM2) is a novel p53 independent proâ€apoptotic gene. International Journal of Cancer, 2009, 125, 2810-2819.	5.1	40
21	Tâ€cell seeding: neonatal transfer of antiâ€myelin basic protein Tâ€cell lines renders Fischer rats susceptible later in life to the active induction of experimental autoimmune encephalitis. Immunology, 2009, 128, 92-102.	4.4	5
22	Capture of Tumor Cell Membranes by Trogocytosis Facilitates Detection and Isolation of Tumor-Specific Functional CTLs. Cancer Research, 2008, 68, 2006-2013.	0.9	37
23	Pneumococcal Capsular Polysaccharide Is Immunogenic When Present on the Surface of Macrophages and Dendritic Cells: TLR4 Signaling Induced by a Conjugate Vaccine or by Lipopolysaccharide Is Conducive. Journal of Immunology, 2008, 180, 2409-2418.	0.8	25
24	Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape. Cancer Research, 2008, 68, 3450-3457.	0.9	29
25	Trogocytosis of MHC-I/Peptide Complexes Derived from Tumors and Infected Cells Enhances Dendritic Cell Cross-Priming and Promotes Adaptive T Cell Responses. PLoS ONE, 2008, 3, e3097.	2.5	41
26	Knockdown of ALR (MLL2) Reveals ALR Target Genes and Leads to Alterations in Cell Adhesion and Growth. Molecular and Cellular Biology, 2007, 27, 1889-1903.	2.3	347
27	O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clinical and Experimental Immunology, 2006, 143, 139-149.	2.6	38
28	Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunology, Immunotherapy, 2006, 56, 217-226.	4.2	13
29	Induction of Antitumor Immunity by CTL Epitopes Genetically Linked to Membrane-Anchored Î²2-Microglobulin. Journal of Immunology, 2006, 176, 217-224.	0.8	20
30	Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy. Cancer Research, 2005, 65, 6435-6442.	0.9	66
31	Membrane-Anchored Î²2-Microglobulin Stabilizes a Highly Receptive State of MHC Class I Molecules. Journal of Immunology, 2005, 174, 2116-2123.	0.8	30
32	Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity. Clinical Cancer Research, 2005, 11, 4955-4961.	7.0	103
33	In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Therapy, 2004, 11, 237-248.	4.6	22
34	Expression of FasL by tumor cells does not abrogate anti-tumor CTL function. Immunology Letters, 2004, 91, 119-126.	2.5	5
35	Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8+ T cell population in different tissues. Vaccine, 2004, 22, 1390-1394.	3.8	14
36	The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood, 2004, 103, 1770-1778.	1.4	62

#	Article	IF	Citations
37	Adoptive Transfer of Colon Cancer Derived Peptide-specific CD8⁺T Cells in HHD Mice. Immune Network, 2004, 4, 31.	3.6	0
38	Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen. Journal of Immunology, 2003, 171, 2197-2207.	0.8	53
39	A Novel Lytic Peptide Composed of dl-Amino Acids Selectively Kills Cancer Cells in Culture and in Mice. Journal of Biological Chemistry, 2003, 278, 21018-21023.	3.4	136
40	CD66a Interactions Between Human Melanoma and NK Cells: A Novel Class I MHC-Independent Inhibitory Mechanism of Cytotoxicity. Journal of Immunology, 2002, 168, 2803-2810.	0.8	163
41	Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. European Journal of Immunology, 2002, 32, 213-222.	2.9	103
42	Characterization of novel breast carcinomaâ€“associated BA46-derived peptides in HLA-A2.1/Db-Î²2mtransgenic mice. Journal of Clinical Investigation, 2002, 110, 453-462.	8.2	30
43	Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Research, 2002, 62, 5835-44.	0.9	44
44	The Role of Platelet Derived Growth Factor (PDGF) and Its Receptors in Cancer and Metastasis. , 2001, , 167-186.		0
45	Antigenicity and Immunogenicity of an Intracellular Delivery System of Major Histocompatibility Complex Class I Epitopes That Bypasses Proteasome Processing. Journal of Immunotherapy, 2000, 23, 622-630.	2.4	3
46	Anti-Tumor Vaccination in Heterozygous Congenic F1 Mice: Presentation of Tumor-Associated Antigen by the Two Parental Class I Alleles. Journal of Immunotherapy, 2000, 23, 344-352.	2.4	0
47	Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. , 2000, 85, 236-242.		1
48	Novel breast-tumor-associated MUC1-derived peptides: Characterization in Dbâ^'/â^' Ã— Î²2 microglobulin (Î²2m) null mice transgenic for a chimeric HLA-A2.1/Db-Î²2 microglobulin single chain. International Journal of Cancer, 2000, 85, 391-397.	5.1	40
49	Antitumor vaccination using peptide based vaccines. Immunology Letters, 2000, 74, 27-34.	2.5	22
50	IFNÎ³ secretion following stimulation with total tumor peptides from autologous human tumors. Journal of Immunological Methods, 2000, 241, 61-68.	1.4	4
51	Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. International Journal of Cancer, 2000, 85, 236-242.	5.1	17
52	Antigen-Specific Antitumor Vaccination: Immunotherapy Versus Autoimmunity. , 2000, , 397-408.		0
53	Induction of Antitumor Immunity with Modified Autologous Cells Expressing Membrane-Bound Murine Cytokines. Journal of Interferon and Cytokine Research, 1999, 19, 1391-1401.	1.2	21
54	Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunology Letters, 1999, 70, 21-28.	2.5	12

#	Article	IF	Citations
55	MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. European Journal of Immunology, 1999, 29, 3295-3301.	2.9	79
56	Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine Interleukin 12. Clinical and Experimental Metastasis, 1998, 16, 623-632.	3.3	16
57	Tumor-Associated Antigen Peptides as Anti-Metastatic Vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	0
58	Tumor-associated antigen peptides as anti-metastatic vaccines. International Journal of Peptide Research and Therapeutics, 1998, 5, 323-328.	0.1	0
59	PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene, 1997, 14, 145-155.	5.9	66
60	Modification of PDGFÎ± receptor expression or function alters the metastatic phenotype of 3LL cells. Oncogene, 1997, 15, 1545-1554.	5.9	10
61	DAP kinase links the control of apoptosis to metastasis. Nature, 1997, 390, 180-184.	27.8	370
62	Curing Metastases? Gene and Peptide Therapy. Current Topics in Microbiology and Immunology, 1996, 213 (Pt 3), 85-100.	1.1	2
63	Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nature Medicine, 1995, 1, 1179-1183.	30.7	143
64	Interleukinâ€6: Effects on Tumor Models in Mice and on the Cellular Regulation of Transcription Factor IRFâ€1a. Annals of the New York Academy of Sciences, 1995, 762, 342-356.	3.8	5
65	Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with newcastle disease virus (NDV). International Journal of Cancer, 1994, 59, 796-801.	5.1	43
66	CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature, 1994, 369, 67-71.	27.8	254
67	The expression of PDGF-Î± but not PDGF-Î² receptors is suppressed in Swiss/3T3 fibroblasts over-expressing protein kinase C-Î±. FEBS Letters, 1994, 342, 165-170.	2.8	5
68	Expression of functionally intact pdgf-Î± receptors in highly metastatic 3ll lewis lung carcinoma cells. International Journal of Cancer, 1993, 53, 315-322.	5.1	14
69	Anti-metastatic vaccination of tumor-bearing mice with il-2-gene-inserted tumor cells. International Journal of Cancer, 1993, 53, 471-477.	5.1	96
70	Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. International Journal of Cancer, 1993, 53, 812-818.	5.1	15
71	Rapid alteration of c-mycand c-junexpression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Letters, 1993, 328, 225-229.	2.8	49
72	Abrogation of B16 Melanoma Metastases by Long-Term Low-Dose Interleukin-6 Therapy. Journal of Immunotherapy, 1993, 13, 98-109.	2.4	27

#	Article	IF	Citations
73	Immunotherapy Via Gene Therapy. Journal of Immunotherapy, 1993, 14, 191-201.	2.4	38
74	The use of [35S]methionine as a target cell label in long term cytotoxic assays. Journal of Immunological Methods, 1992, 149, 255-260.	1.4	12
75	Differentiation patterns of CD4CD8 thymocyte subsets in cocultures of fetal thymus and lymphohemopoietic cells from c-fos transgenic and normal mice. Cellular Immunology, 1992, 141, 279-292.	3.0	2
76	H-2Db gene transfer into highly metastatic D122 cells results in tumor rejection in allogeneic recipients, but does not affect metastasis in syngeneic recipients. Implications for mechanisms of allorejection. International Journal of Cancer, 1992, 52, 771-777.	5.1	8
77	Fertility Impairment and Improved Fetal Survival Induced by a Tumor Cell Line in Mice. American Journal of Reproductive Immunology, 1991, 26, 47-52.	1.2	3
78	Immunization by gamma-IFN-treated B16-F10.9 melanoma cells protects against metastatic spread of the parental tumor. International Journal of Cancer, 1991, 47, 54-60.	5.1	23
79	T-cell subset analysis of 3LL tumor growth. International Journal of Cancer, 1991, 47, 69-72.	5.1	0
80	Immunogenic capacity of macrophage hybridomas. European Journal of Immunology, 1989, 19, 89-96.	2.9	1
81	Oncogenes and Tyrosine Kinase Activities as a Function of the Metastatic Phenotype. , 1986, , 57-70.		2
82	The differential expression of H-2K versus H-2D antigens, distinguishing high- metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. International Journal of Cancer, 1984, 34, 567-573.	5.1	106
83	MHC imbalance and metastatic spread in Lewis lung carcinoma clones. International Journal of Cancer, 1983, 32, 113-120.	5.1	126
84	Electrophoretic mobility of membrane fragments on a sucrose gradient. Analytical Biochemistry, 1979, 92, 228-232.	2.4	6
85	Porcine Carboxypeptidase B. Arsanilazocarboxypeptidase, Spectral and Functional Consequences of Modification of Tyrosine-"248". FEBS Journal, 1972, 25, 483-490.	0.2	13